Islet Cell Therapies Advance: What You Need to Know

For over a century, insulin replacement has been the primary treatment for Type 1 diabetes. Now, researchers are pursuing a different path: replacing the insulin-producing cells that the immune system destroys. Islet cell therapies—which transplant functional beta cells into people with Type 1 diabetes—are moving from the laboratory into clinical trials with encouraging early results.

In these trials, participants have achieved healthy blood sugar levels and reduced or eliminated their need for external insulin. While these outcomes are significant, it's important to note that islet cell therapies are not yet widely available. Current first-generation therapies are limited to people with severe hypoglycemic episodes and hypoglycemia unawareness—conditions where blood sugar drops dangerously low and the body cannot sense it happening.

The real breakthrough on the horizon is manufactured islet cells—cells created in the laboratory rather than from donor tissue. These manufactured versions could eventually be produced at scale, making them accessible to far more people than current therapies.

To accelerate this progress, major research organizations recently convened a public workshop titled 'Accelerating the Translation of Cell Therapy for Type 1 Diabetes.' Breakthrough T1D co-hosted the event with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), bringing together researchers, clinicians, industry leaders, FDA representatives, and people with Type 1 diabetes. The workshop focused on practical challenges: how to develop these cells in the lab, how to manufacture them reliably at scale, and how to design clinical trials that will prove their safety and effectiveness.

The vision driving this work is clear: a future where anyone with Type 1 diabetes who wants an islet cell therapy can receive one.

While cell replacement therapies advance, another strategy is gaining traction: catching Type 1 diabetes early and slowing its progression. Type 1 diabetes has a presymptomatic phase—a window of time before insulin therapy becomes necessary when the immune system is attacking pancreatic beta cells but blood sugar remains relatively normal. Detecting people during this early stage opens the door to intervention.

Recent FDA approval of teplizumab, an immunotherapy that delays the onset of clinical Type 1 diabetes, has intensified interest in identifying people in these early stages. Researchers are refining screening approaches to identify individuals at risk, knowing that early treatment could preserve the body's own insulin production longer and potentially reduce disease burden.

These two strategies—immunotherapy to slow disease progression and cell therapy to replace lost function—represent complementary paths forward in transforming how Type 1 diabetes is managed.

Origin: breakthrought1d.org (News report). Evidence: News report, corroborated with 3 indexed studies. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.